| Literature DB >> 29560133 |
Yan Yan1, Ai-Ping Deng2, Wen Chen3, Yu-Hua Ming1, Xian-Tao Zeng1, Wei-Dong Leng1.
Abstract
BACKGROUND: The human 8-oxoguanine glycosylase 1 (hOGG1) Ser326Cys polymorphism has been involved in the risk of head and neck squamous cell carcinoma (HNSCC), but the results of published studies on this topic still inconsistent.Entities:
Keywords: hOGG1; head and neck squamous cell carcinoma; human 8-oxoguanine glycosylase 1; meta-analysis; polymorphism
Year: 2018 PMID: 29560133 PMCID: PMC5849197 DOI: 10.18632/oncotarget.24055
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Flowchart of study section in the meta-analysis
Characteristics of all included studies in the meta-analysis
| References | Country (Ethnicity) | Tumor site | Cases/ Controls | Source of control | Genotyping method | HWE | |||
|---|---|---|---|---|---|---|---|---|---|
| N. | SerSer | CysSer | CysCys | ||||||
| Elahi 2002 | USA (Caucasian) | Oropharynx | 169/338 | 104/249 | 54/76 | 9/6 | PB | PCR-RFLP | Yes |
| Cho 2003 | China (Asian) | Nasopharynx | 334/283 | 36/46 | 175/129 | 122/108 | PB | PCR-RFLP | Yes |
| Zhang 2004 | USA (Caucasian) | HNSCC | 706/1196 | 447/739 | 220/388 | 39/69 | HB | PCR-RFLP | Yes |
| Gorgens 2007 | Germany (Caucasian) | HNSCC | 29/30 | 19/19 | 8/10 | 2/1 | PB | PCR | Yes |
| Hall 1 2007 | EE (Caucasian) | Oral cavity | 160/754 | 98/485 | 52/253 | 1016 | HB | Taqman | No |
| Hall 2 2007 | EE (Caucasian) | Pharynx | 107/754 | 65/485 | 35/23 | 7/16 | HB | Taqman | No |
| Hall 3 2007 | EE (Caucasian) | Larynx | 312/754 | 206/485 | 98/23 | 8/16 | HB | Taqman | No |
| Yang 2008 | China (Asian) | Larynx | 72/72 | 34/50 | 34/22 | 4/0 | HB | PCR-RFLP | Yes |
| Pawlowska 2009 | Poland (Caucasian) | Larynx | 253/253 | 141/166 | 91/77 | 21/10 | HB | PCR-RFLP | Yes |
| Laantri 2011 | African (North African) | Nasopharynx | 598/545 | 289/274 | 202/193 | 50/39 | PB | TaqMan | Yes |
| Mitra 2011 | India (Caucasian) | HNSCC | 250/325 | 110/105 | 118/171 | 7/26 | PB | PCR-RFLP | No |
| Sliwinski 2011 | Poland (Caucasian) | Larynx | 265/280 | 109/160 | 128/111 | 28/9 | PB | PCR-RFLP | No |
| Tsai 2012 | China (Asian) | Oral cavity | 620/620 | 138/104 | 252/251 | 230/265 | HB | PCR-RFLP | No |
Notes: EE, Eastern European (Romania, Poland, Russia, Slovakia, and Czech Republic); African, Morocco, Algeria and Tunisia; HNSCC, head and neck squamous cell carcinoma; N., sample size; HWE, Hardy-Weinberg equilibrium.
The results of overall and subgroup analysis of the all genetic models
| N. | Cys vs. Ser | CysCys vs. SerSer | CysSer vs. SerSer | (CysCys+ CysSer) vs. SerSer | CysCys vs. (CysSer + SerSer) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95%CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |||||||
| Overall | 13 | 1.16 | 81.5 | 1.55 (1.01–2.38) | 79.6 | 1.11 (0.93–1.33) | 67.2 | 1.16 (0.95–1.42) | 77.2 | 1.42 (1.005–1.99) | 74.3 |
| Ethnicity | |||||||||||
| Caucasian | 9 | 1.19 | 82.0 | 1.79 (0.97–3.30) | 79.3 | 1.09 (0.88–1.34) | 65.7 | 1.15 (0.90–1.47) | 77.2 | 1.73 (1.01–2.97) | 74.1 |
| Asian | 3 | 1.14 | 86.5 | 1.15 (0.49–2.71) | 80.5 | 1.38 (0.68–2.80) | 84.7 | 1.36 (0.63–2.93) | 88.2 | 0.87 (0.65–1.17) | 40.0 |
| North African | 1 | 1.06 | NA | 1.22 (0.77–1.91) | NA | 0.99 (0.77–1.28) | NA | 1.03 (0.81–1.31) | NA | 1.22 (0.79–1.89) | NA |
| Tumor site | |||||||||||
| Larynx | 4 | 1.49 | 80.6 | 2.65 (1.27–5.54) | 53.1 | 1.40 (0.97–1.33) | 72.0 | 1.53 (1.01–2.33) | 79.5 | 2.29 (1.29–4.08) | 30.3 |
| Oral cavity | 2 | 0.98 | 85.8 | 1.36 (0.30–6.21) | 91.7 | 0.86 (0.65–1.15) | 31.2 | 0.89 (0.55–1.42) | 77.3 | 1.47 (0.39–5.55) | 90.1 |
| Nasopharynx | 2 | 1.07 | 0 | 1.31 (0.94–1.84) | 0 | 1.26 (0.73–2.16) | 74.2 | 1.22 (0.80–1.87) | 62.8 | 1.03 (0.79–1.34) | 0 |
| Source of control | |||||||||||
| Population-based | 6 | 1.17 | 85.4 | 1.50 (0.72–3.12) | 81.2 | 1.21 (0.85–1.72) | 77.0 | 1.24 (0.84–1.83) | 83.0 | 1.30 (0.72–2.36) | 77.1 |
| Hospital-based | 7 | 1.14 | 78.3 | 1.60 (0.91–2.82) | 79.4 | 1.02 (0.85–1.23) | 50.9 | 1.09 (0.87–1.36) | 70.0 | 1.56 (0.96–2.55) | 75.4 |
| Smokers | 4 | 1.40 | 90.3 | 1.73 (0.54–5.56) | 84.2 | 1.40 (0.78–2.51) | 80.4 | 1.34 (0.69–2.62) | 86.9 | 1.64 (0.67–3.98) | 75.0 |
| Alcohol drinkers | 2 | 1.62 | 0 | 2.54 (0.72–8.95) | 58.5 | 1.67 (1.19–2.35) | 0 | 1.75 (1.26–2.42) | 0 | 2.15 (0.58–8.02) | 62.7 |
| HWE | 7 | 1.26 | 71.8 | 1.53 (1.04–2.24) | 47.0 | 1.29 (1.00–1.65) | 63.2 | 1.35 (1.04–1.76) | 70.0 | 1.28 (0.92–1.78) | 43.9 |
| PCR-RFLP | 8 | 1.20 | 88.7 | 1.42 (0.79–2.56) | 84.9 | 1.23 (0.92–1.63) | 80.0 | 1.26 (0.91–1.75) | 86.3 | 1.22 (0.80–1.86) | 77.8 |
Notes: OR, odd ratio; CI, confidence interval; N., number of case-control studies; HWE, Hardy-Weinberg equilibrium; NA, not available.
Figure 2Forest plot of overall population based on CysCys vs. SerSer genetic model
Figure 3Trial sequential analysis of CysCys vs. SerSer genetic model
CC, CysCys; GG, SerSer; a low risk diversity adjusted information size of 3490 patients was calculated using α = 0.05 (two sided), β = 0.20 (power 80%); TSA adjusted 95% confidence interval for a odds ratio of 1.55 is 1.01 to 2.38 based on random-effects model. TSA illustrated that the cumulative z curve crossed the conventional boundary and the trial sequential monitoring boundary for increased risk, and that the required information size was achieved, showing that currently cumulative evidence might be true positive
Figure 4Forest plot of sensitivity analysis based on CysCys vs. SerSer model by omitting each study in turn
Figure 5Forest plot of cumulative meta-analysis based CysCys vs. SerSer model by accumulating each study according to the publication year
Figure 6Funnel plots based on the trim and fill method of CysCys vs. SerSer model